Real-world effectiveness and safety of pazopanib in patients with intermediate prognostic risk advanced renal cell carcinoma
Hawkins, Robert E
AffiliationDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
MetadataShow full item record
AbstractINTRODUCTION: The objective of this study was to determine the effectiveness and safety of pazopanib in patients with intermediate-risk advanced/metastatic renal cell carcinoma in the PRINCIPAL study (NCT01649778). PATIENTS AND METHODS: Patients had clear-cell advanced/metastatic renal cell carcinoma and met intermediate-risk International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and Memorial Sloan Kettering Cancer Center (MSKCC) criteria. Assessments included progression-free survival, overall survival, objective response rate, and safety. We also evaluated effectiveness based on number of risk factors, age, and performance status (PS), as well as safety in older and younger patients. RESULTS: Three hundred sixty three and 343 intermediate-risk MSKCC and IMDC patients were included, respectively. The median progression-free survival was 13.8 months (95% confidence interval [CI], 10.7-18.1 months) and 7.4 months (95% CI, 6.2-10.3 months) for patients with 1 and 2 MSKCC risk factors, respectively, and 13.1 months (95% CI, 10.7-18.1 months) and 8.1 months (95% CI, 6.4-10.7 months) for patients with 1 and 2 IMDC risk factors, respectively. The median overall survival was not reached and was 15.2 months (95% CI, 12.3-26.5 months) for patients with 1 and 2 MSKCC risk factors, respectively, and 33.9 months (95% CI, 33.9 months to not estimable) and 19.4 months (95% CI, 14.3 months to not estimable) with 1 and 2 IMDC risk factors, respectively. A lower overall response rate was observed with Eastern Cooperative Oncology Group PS ³ 2 (vs. PS < 2). All-grade treatment-related adverse events occurred in approximately 63% of patients, and the safety profile among older and younger patients was similar. CONCLUSIONS: Outcomes with pazopanib in intermediate-risk patients suggest that patients can be further stratified by number of risk factors (1 vs. 2) and Eastern Cooperative Oncology Group PS (< 2 vs. ³ 2) to more accurately predict outcomes.
CitationProcopio G, Bamias A, Schmidinger M, Hawkins R, Sanchez AR, Estevez SV, et al. Real-world effectiveness and safety of pazopanib in patients with intermediate prognostic risk advanced renal cell carcinoma. Clin Genitourin Cancer. 2019;17(3).
JournalClinical Genitourinary Cancer
- Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study).
- Authors: Schmidinger M, Bamias A, Procopio G, Hawkins R, Sanchez AR, Vázquez S, Srihari N, Kalofonos H, Bono P, Pisal CB, Hirschberg Y, Dezzani L, Ahmad Q, Jonasch E, PRINCIPAL Study Group.
- Issue date: 2019 Apr
- A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma.
- Authors: Kim MJ, Park SH, Lee JL, Lee SH, Lee SJ, Lim HY
- Issue date: 2016 Aug 2
- Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial.
- Authors: Tannir NM, Msaouel P, Ross JA, Devine CE, Chandramohan A, Gonzalez GMN, Wang X, Wang J, Corn PG, Lim ZD, Pruitt L, Karam JA, Wood CG, Zurita AJ
- Issue date: 2020 Oct
- Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy.
- Authors: Kang HC, Gupta S, Wei W, Lu L, Matrana MR, Tannir NM, Choi H
- Issue date: 2017 Dec
- Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study.
- Authors: Masini C, Vitale MG, Maruzzo M, Procopio G, de Giorgi U, Buti S, Rossetti S, Iacovelli R, Atzori F, Cosmai L, Vignani F, Prati G, Scagliarini S, Guida A, Berselli A, Pinto C
- Issue date: 2019 Feb